Bladder Cancer

Bladder cancer is one of the cleaner ratings in the VA schedule while it's active and one of the more contested once it isn't. Under 38 CFR § 4.115b, diagnostic code 7528 assigns a flat 100 percent evaluation for a malignant neoplasm of the genitourinary system. There are no intermediate tiers during the active-disease phase. Diagnosis plus pathology plus an ongoing course of treatment equals total disability. That part rarely produces a fight.

The fight comes later. DC 7528 is a two-phase code. The 100 percent rating runs through surgical, radiation, chemotherapy, or other therapeutic treatment, and then for six months after that treatment ends a mandatory VA examination is scheduled. If that exam shows no local recurrence and no metastasis, the cancer stops being rated as cancer. It gets rated on its residuals instead, either as voiding dysfunction or as renal dysfunction under 38 CFR § 4.115a, whichever produces the higher evaluation. That conversion, and the procedural protections that surround it, is where most of the actual rating analysis lives.

This page walks through both phases: the 100 percent active-cancer rule under DC 7528, the mandatory 6-month examination and the § 3.105(e) reduction protections that attach to it, the voiding-versus-renal residual fork under § 4.115a, the C&P mechanics that decide which residual path applies, and the toxic-exposure presumptive pathways (Agent Orange, burn pits, contaminated water) that have made bladder cancer one of the higher-grant conditions in the dataset.

TL;DR

• Bladder cancer is rated under 38 CFR § 4.115b, DC 7528 (malignant neoplasms of the genitourinary system).
• During active disease and treatment, the rating is a flat 100 percent. There are no partial tiers in the active phase.
• After treatment ends, a mandatory VA examination is scheduled at the 6-month mark. The 100 percent continues until that exam happens.
• If there is no local recurrence and no metastasis, the cancer converts to a residual rating under § 4.115a, rated on either voiding dysfunction or renal dysfunction, whichever is predominant.
• Any reduction from 100 percent follows the procedural protections of 38 CFR § 3.105(e), including advance notice and the chance to respond.
• Voiding dysfunction is rated on the specific problem: urine leakage and absorbent-pad changes per day, urinary frequency, or obstructed voiding. Renal dysfunction is rated on labs (BUN, creatinine, albuminuria) and dialysis.
• Bladder cancer has recognized toxic-exposure pathways. It was added as an Agent Orange presumptive, and it is associated with burn-pit and contaminated-water exposure under the PACT Act framework.
• In Claim Raven's analysis of 502 BVA bladder cancer cases, 47.4% were granted, 9.4% remanded, and 43.2% denied. Of 303 cases with a C&P adequacy determination, 39.6% had the exam flagged as inadequate. The grant share is high and the remand share is very low relative to most conditions, consistent with the presumptive pathways and the clear-cut 100% active-cancer rule.

DC 7528 and the 100 Percent Active-Cancer Rule

The entire genitourinary cancer family sits under DC 7528 in 38 CFR § 4.115b. The structure of the code is short, and reading it carefully matters because almost every dispute turns on a phrase in it.

"Malignant neoplasms of the genitourinary system, 100% Note: Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant."

Two things to pull out of that text.

First, the 100 percent is automatic for the active phase. There is no "moderate" or "severe" bladder cancer tier. A confirmed malignant neoplasm of the bladder that is being treated rates 100 percent, full stop. The rating analysis at this stage is binary: is the cancer service-connected, and is it active or under treatment. If yes to both, the evaluation is total.

Second, the 100 percent does not end on its own. It "shall continue" until the mandatory examination at the six-month point after treatment cessation. The clock starts when the last therapeutic procedure ends, not when the cancer is first diagnosed and not on some fixed calendar date. That detail matters in cases where treatment is staged or where a recurrence restarts the course of therapy.

The Mandatory 6-Month Exam and § 3.105(e) Protection

The conversion from cancer rating to residual rating is the most procedurally protected event in this code, and it is also where veterans lose ground when they don't understand the timeline.

The note in DC 7528 schedules a mandatory VA examination at the expiration of six months following the cessation of treatment. The purpose of that exam is to determine whether the cancer is still present: is there local recurrence, is there metastasis. If the exam shows active or recurrent disease, the 100 percent continues. If the exam shows no recurrence and no metastasis, the predicate for the 100 percent rating is gone, and the rating converts to a residual evaluation.

Here is the protection. Any reduction that flows from that exam is governed by 38 CFR § 3.105(e). When a rating reduction would reduce the compensation actually paid, VA has to issue a proposed reduction, give the veteran 60 days to submit evidence, give 30 days to request a predetermination hearing, and only then issue a final action. The reduction takes effect prospectively, not retroactively. A veteran who gets a letter proposing to drop the bladder cancer rating from 100 percent has a defined window to respond, and VA cannot simply flip the rating the day after the exam.

The most common BVA error pattern I see in this code is a reduction that skips or fumbles the § 3.105(e) steps. When the procedural sequence is defective, the reduction is void regardless of whether the medical picture supported it, and the 100 percent gets restored. That is one reason the remand share in this subset is low and the grant share is comparatively high: when the cancer is genuinely service-connected, the active-phase rating is hard to dispute, and procedural reduction errors break in the veteran's favor.

The Residual Fork: Voiding Dysfunction vs Renal Dysfunction

Once the cancer is in remission and the conversion happens, the rating runs on residuals under § 4.115a. The regulation tells the rater to evaluate the condition as "voiding dysfunction or renal dysfunction, whichever is predominant." Those are two different rating systems, and the choice between them drives the number.

This is the single most important mechanical point on the page. The rater does not pick the path that is easiest to document. The rater is supposed to identify which residual is predominant, meaning which one most disables you, and rate under that one.

Voiding dysfunction is the more common residual after bladder cancer treatment, because the bladder itself is the treated organ. Surgery, intravesical therapy, and radiation all tend to leave the veteran with problems storing or emptying urine. Under § 4.115a, voiding dysfunction is rated on whichever of three particular conditions is the actual problem:

"Voiding dysfunction: Rate particular condition as urine leakage, frequency, or obstructed voiding."

The three sub-paths each have their own criteria. Continual urine leakage, post-surgical urinary diversion, urinary incontinence, or stress incontinence is rated by the degree of absorbent-material management, with the highest tier requiring the use of an appliance or the changing of absorbent materials more than a set number of times per day. Urinary frequency is rated on daytime voiding intervals and the number of times the veteran wakes to void at night. Obstructed voiding is rated on flow markers such as hesitancy, a weakened stream, post-void residual volume, and the need for dilatation or catheterization.

Renal dysfunction is the other branch. It applies when the kidney function is the predominant residual, which happens less often after a bladder primary but does occur, particularly where treatment or an ileal conduit affects upstream renal function. Renal dysfunction is rated on objective markers: BUN and creatinine levels, albuminuria, hypertension associated with renal involvement, and whether the veteran requires regular dialysis. Dialysis dependence rates at the top of the renal schedule.

The reason this fork matters is that the two systems do not produce the same numbers from the same clinical picture. A veteran with significant incontinence requiring frequent pad changes can rate high under voiding dysfunction while having normal labs that would rate low under renal dysfunction. The regulation's "whichever is predominant" instruction is supposed to route you to the higher-disability path. When a decision rates a clearly incontinent veteran under a renal framework with normal kidney labs, that is a misapplication of the fork, and it is appealable.

C&P Exam Mechanics: What the Examiner Has to Measure

The conversion exam and any later residual exam follow the genitourinary DBQ. The exam is the rating engine, and which residual path applies depends entirely on what the examiner documents.

For the cancer-status question, the examiner has to confirm whether there is active disease, local recurrence, or metastasis, and identify the date the last treatment ended. That date sets the six-month clock and determines whether a conversion is even ripe.

For the voiding-dysfunction path, the examiner should record:

• Urine leakage and the type of management: the number of absorbent pads or the number of pad or appliance changes per day, and whether an appliance is required
• Urinary frequency: daytime voiding interval and nighttime awakenings to void
• Obstructed voiding markers: hesitancy, stream strength, post-void residual volume, and any need for catheterization or dilatation
• Any urinary tract infection history and recurrent treatment

For the renal-dysfunction path, the examiner should document BUN, creatinine, the presence and degree of albuminuria, blood pressure with any renal-associated hypertension, and dialysis status.

When all of these components are in the report, the rater can identify the predominant residual and rate it correctly. When the exam is sparse, the rater defaults to whatever is documented, which is usually the cancer-status finding plus a thin residual note. That is the mechanism behind the 39.6 percent inadequate-exam rate in the cases that carried an adequacy determination: the exam confirms remission but never develops the residual picture in enough detail to support the voiding tiers, so the conversion lands at a lower number than the veteran's actual symptoms warrant.

Toxic-Exposure Pathways: Agent Orange, Burn Pits, and Contaminated Water

Bladder cancer is one of the conditions where the service-connection theory is often stronger than the rating math, because the disease sits inside recognized toxic-exposure frameworks. Establishing the exposure and the pathology can carry the service-connection element without a contested nexus fight.

Bladder cancer was added to the list of diseases associated with herbicide (Agent Orange) exposure. For a veteran with qualifying exposure, that presumptive status means service connection can be established on the exposure and the diagnosis without proving a direct in-service cause, when the regulatory criteria are met.

The PACT Act framework expanded the toxic-exposure picture further. Bladder cancer is associated with burn-pit and other airborne-hazard exposure and with contaminated-water exposure under that framework. A veteran who served where qualifying burn-pit exposure is recognized, or who was exposed to contaminated water at a covered location, has a recognized exposure pathway to connect.

The practical point: in this subset, the cases that grant tend to pair a documented exposure with confirmed pathology. The exposure establishes the pathway, the biopsy or surgical pathology report confirms the malignancy, and the active-cancer rule supplies the 100 percent. That combination is why the grant share in the data sits well above what I see for most musculoskeletal or mental-health conditions, and why remands are rare: there is less for the Board to send back when the exposure is presumptive and the pathology is in the file.

If your bladder cancer is tied to one of these exposure pathways, the file should preserve the exposure proof (unit and location records, dates of service, the covered-location or qualifying-service documentation) alongside the pathology. The secondary conditions tool can help map exposure-driven and downstream conditions that travel with a genitourinary cancer.

Common Evidence Gaps in Bladder Cancer Claims

A few patterns I've noticed across BVA decisions involving bladder cancer. These are qualitative reads from the case texts, not separate measured statistics.

Treatment-cessation date not pinned down. The six-month clock under DC 7528 runs from the cessation of treatment. When the record is vague about when the last therapeutic procedure ended, or when intravesical therapy was given in cycles, the conversion timing gets muddled. A clear treatment-end date in the oncology record protects the full active-phase 100 percent.

Residual exam developed for the cancer, not the residuals. The conversion exam often confirms remission and stops there. It records "no recurrence" but never quantifies pad changes per day, voiding intervals, or obstructed-voiding markers. Without that detail, the rater cannot route the rating to the predominant residual, and the converted rating undershoots the veteran's actual symptoms. This is the gap that the 39.6 percent inadequate-exam figure most often reflects.

Wrong fork applied. A veteran with significant incontinence gets rated under a renal framework, or a veteran with genuine renal involvement gets squeezed into voiding criteria. The regulation says rate "whichever is predominant." A residual picture that documents both, and argues which one most disables you, keeps the rater on the higher-disability path.

§ 3.105(e) reduction skipped or rushed. When VA proposes to drop the rating from 100 percent after the conversion exam, the procedural sequence (proposed reduction, 60-day evidence window, 30-day hearing-request window, prospective effective date) has to be followed. A reduction that skips a step is void on procedure alone, regardless of the medical picture.

Exposure proof missing even when the pathway exists. A veteran with a qualifying Agent Orange, burn-pit, or contaminated-water exposure may have the diagnosis in the file but not the exposure documentation that activates the presumptive pathway. Unit records, location and date records, and covered-service documentation turn a contested direct claim into a cleaner presumptive one.

Bottom Line

Bladder cancer is two ratings wearing one diagnostic code. While the cancer is active and under treatment, DC 7528 pays a flat 100 percent, and that part is hard to dispute when the disease is service-connected, which is a large reason the grant share in the data is high and the remand share is low. The contested phase is the conversion. Six months after treatment ends, a mandatory exam decides whether the cancer is gone, and if it is, the rating drops to a residual evaluation on either voiding or renal dysfunction. The two paths produce different numbers, the regulation routes you to whichever residual is predominant, and § 3.105(e) gives you procedural protection on the way down. The cases that hold their value are the ones where the treatment-end date is documented, the conversion exam quantifies the actual residual symptoms, the correct fork is applied, and, where the disease ties to a toxic exposure, the exposure proof sits in the file next to the pathology. Same diagnosis, different paper trail, different outcome.

Related Conditions

Bladder cancer claims commonly connect to other genitourinary pages because the residual rating systems and the exposure pathways overlap. See prostate cancer and the prostate page, which run on the same DC 7528 active-cancer rule and the same voiding-versus-renal residual fork. The bladder page covers non-malignant bladder conditions rated directly on voiding dysfunction, and kidney disease covers the renal-dysfunction side of § 4.115a in more depth. Veterans with a genitourinary cancer should also review the secondary conditions tool to map exposure-driven and downstream conditions.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.115b, DC 7528, and the residual schedules at § 4.115a. Reduction procedure from 38 CFR § 3.105(e). Toxic-exposure pathways reflect the Agent Orange herbicide presumptive list and the PACT Act framework for burn-pit and contaminated-water exposure. Outcome and exam-adequacy figures from Claim Raven's analysis of BVA decisions.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 502 bladder cancer cases. Within that subset, outcomes ran 47.4% granted, 9.4% remanded, and 43.2% denied. Of the 303 cases that carried a C&P adequacy determination, 39.6% had the examination flagged as inadequate. The dataset captures overall case outcome rather than a per-residual-path (voiding vs renal) breakdown.
• Classification approach: Diagnostic code and residual definitions drawn from the regulatory text. The conversion and reduction analysis follows the DC 7528 note and § 3.105(e). Exposure-pathway descriptions follow the recognized presumptive frameworks. I describe the relative grant and remand shares qualitatively against the broader dataset rather than asserting a causal claim about why each case resolved as it did.
• Limitations:
• The 100 percent active-cancer rating and the six-month mandatory exam are set by the DC 7528 note. Application of the conversion timing varies where treatment is staged or where a recurrence restarts the treatment course.
• Whether the predominant residual is voiding or renal dysfunction is fact-specific. The schedule routes the rating to whichever is predominant, but identifying the predominant residual depends on the quality of the exam.
• Presumptive status depends on meeting the specific service, location, and timeframe criteria for the relevant exposure framework. Not every veteran with bladder cancer qualifies for a presumptive pathway.
• Selection bias: BVA-level patterns reflect cases that appealed. Most bladder cancer claims resolve at the RO level and are not in any BVA dataset. The comparatively high grant share in this subset should be read in that light.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.